United States· US:71610-017_8527dc6d-ebec-4ba3-91be-59553b69aef6
Sucralfate
A sucralfate product containing sucralfate, registered in United States by Aphena Pharma Solutions - Tennessee, LLC. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Sucralfate is registered in 13 of 19 countries.
Countries holding a registration under ATC A02BX02 (sucralfate), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Sucralfate · ATC A02BX02
13 / 19 countries
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sucralfate costs, country by country.
Normalised to the WHO defined daily dose (4 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sucralfate · price per daily dose (4 g)
USD · FX 28 Sept 2026
- IT Italy$0.62
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- SUCRALFATE
- Manufacturer
- Aphena Pharma Solutions - Tennessee, LLC
- Country
- United States (US)
- ATC code
- A02BX02
- ATC class
- Sucralfate
- Defined daily dose
- 4 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc1171610-017-60
- ndc1171610-017-70
- ndc1171610-017-94
- ndc11716100176090 TABLET in 1 BOTTLE (71610-017-60)
- ndc117161001770120 TABLET in 1 BOTTLE (71610-017-70)
- ndc117161001794360 TABLET in 1 BOTTLE (71610-017-94)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
504 interactions on record for sucralfate.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sucralfate · interactions on record
504 records
- 5 severe
- 116 moderate
- 46 minor
- 337 info
Most severe, free to view
- ParicalcitolA11CC07severe
- ParicalcitolH05BX02severe
- DoxercalciferolH05BX03severe
- DolutegravirJ05AJ03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sucralfate in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandAlsucralOrion Corporation Orion Pharma
- CanadaAPO-SUCRALFATE - TAB 1GAPOTEX INC
- SwedenAndapsin 1 g TablettOrion Corporation
- ItalyANTEPSINLABORATORI BALDACCI S.P.A.
- FranceKEAL 1 g, comprimé sécableEXOD
- NorwayAntepsinOrion Corporation Orion Pharma
- CzechiaGASTROFAIT
- NetherlandsPeptonorm 1 g, tablettenUni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Austria · Sucralan, Sucralfat Genericon
- Germany · Sucrabest
- Denmark · Antepsin, Peptonorm
- Finland · Antepsin, Peptonorm
- France · Keal, Ulcar
- United Kingdom (Northern Ireland) · Sucralfate Roma Pharmaceuticals
- Greece · Peptonorm
- Hungary · Peptonorm
- Iceland · Antepsin
- Italy · Antepsin, Sucralfato Doc Generici
- Netherlands · Sucralfaat Sandoz, Sucralfaat Teva
- Norway · Antepsin
- Portugal · Sucralfato Generis, Sucralfato Jaba
- Sweden · Andapsin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a8c64223-63fe-4c4d-be6a-944f29641349 GET /v1/drugs/a8c64223-63fe-4c4d-be6a-944f29641349?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "1",
"substance": "SUCRALFATE",
"productndc": "71610-017",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "g/1",
"application_number": "NDA018333",
"marketing_category": "NDA AUTHORIZED GENERIC"
}See everything about sucralfate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.